Aurinia Pharmaceuticals Inc is a biopharmaceutical company based in Edmonton, Canada, dedicated to the development and commercialization of treatments for diseases lacking sufficient medical solutions. Its flagship product, LUPKYNIS, is designed for adults with active lupus nephritis, showcasing the company's focus on addressing significant unmet medical needs. Aurinia Pharmaceuticals also collaborates with Otsuka Pharmaceutical Co., Ltd., highlighting its commitment to expanding its impact and reach in healthcare.
Berkshire Hathaway has resumed acquiring shares of Warren Buffett's favorite media stock. Other insider buyers are focused on three biotech stocks.
Officers, beneficial owners, and other insiders have shelled out more than $10 million on each of these four biotech stocks in the past week.
The most notable insider purchases of stock in the past week were in biotech and energy companies, as well as a specialty retailer.
